Cidara Therapeutics Stock Forecast, Price & News

Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

Is Cidara Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Cidara Therapeutics stock.
View analyst ratings for Cidara Therapeutics or view top-rated stocks.

How has Cidara Therapeutics' stock price been impacted by Coronavirus?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDTX shares have decreased by 41.1% and is now trading at $1.46.
View which stocks have been most impacted by COVID-19.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cidara Therapeutics.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.01. Cidara Therapeutics had a negative net margin of 106.76% and a negative trailing twelve-month return on equity of 722.37%.
View Cidara Therapeutics' earnings history.

What price target have analysts set for CDTX?

2 brokerages have issued 12-month price targets for Cidara Therapeutics' shares. Their forecasts range from $6.25 to $8.00. On average, they expect Cidara Therapeutics' stock price to reach $7.13 in the next year. This suggests a possible upside of 388.0% from the stock's current price.
View analysts' price targets for Cidara Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:

• Jeffrey L. Stein, President, Chief Executive Officer & Director (LinkedIn Profile)
• Paul Daruwala, Chief Operating Officer (LinkedIn Profile)
• Preetam Shah, Chief Financial & Business Officer (LinkedIn Profile)
• Les Tari, Senior Vice President-Research
• Taylor Sandison, Chief Medical Officer

Who are some of Cidara Therapeutics' key competitors?

Some companies that are related to Cidara Therapeutics include Passage Bio (PASG), Cellectis (CLLS), Innate Pharma (IPHYF), Molecular Partners (MOLN), Cortexyme (CRTX), Lineage Cell Therapeutics (LCTX), SQZ Biotechnologies (SQZ), DBV Technologies (DBVT), Cabaletta Bio (CABA), Acumen Pharmaceuticals (ABOS), Opthea (OPT), Compugen (CGEN), Jasper Therapeutics (JSPR), Candel Therapeutics (CADL) and Codiak BioSciences (CDAK).
View all of CDTX's competitors.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (9.65%), Altium Capital Management LP (2.57%), Renaissance Technologies LLC (2.26%), Stonepine Capital Management LLC (1.58%), Two Sigma Advisers LP (0.95%) and Geode Capital Management LLC (0.77%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian, Paul Daruwala, Preetam Shah and Timothy R Franson.
View institutional ownership trends for Cidara Therapeutics.

Which institutional investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Millennium Management LLC, BlackRock Inc., Squarepoint Ops LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian, and Paul Daruwala.
View insider buying and selling activity for Cidara Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Cidara Therapeutics stock?

CDTX stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, BVF Inc. IL, Two Sigma Advisers LP, Monashee Investment Management LLC, Two Sigma Investments LP, Marshall Wace LLP, Renaissance Technologies LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, Jeffrey Stein, Preetam Shah, and Timothy R Franson.
View insider buying and selling activity for Cidara Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $1.46.

How much money does Cidara Therapeutics make?

Cidara Therapeutics has a market capitalization of $97.36 million and generates $12.07 million in revenue each year. The biotechnology company earns $-72.11 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Cidara Therapeutics have?

Cidara Therapeutics employs 79 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

Where are Cidara Therapeutics' headquarters?

Cidara Therapeutics is headquartered at 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 752-6170 or via email at [email protected].